A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer. Researchers discuss the findings.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

These open-world games feature unique player progression styles that are different from most standard open-world titles.

The following is a summary of “Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression,” published in the April 2025 issue of BMC ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel). In a press ...

The lackluster overall survival data came in stark contrast with the massive 78% and 60% progression-free survival improvements that Cabometyx has shown in the two patient subgroups, respectively.